# Salivary excretion of systemically injected [18F]DCFPyL in prostate cancer patients undergoing PSMA scans

## TL;DR

This study shows that [18F]DCFPyL, a radiotracer used in prostate cancer imaging, is excreted in saliva over time after injection.

## Contribution

The study is the first to demonstrate salivary excretion of [18F]DCFPyL in prostate cancer patients.

## Key findings

- Salivary glands showed high uptake of [18F]DCFPyL in all 10 patients.
- Eight patients demonstrated high uptake of [18F]DCFPyL in saliva at 45 minutes post-injection.
- Intact [18F]DCFPyL was confirmed in saliva samples at 120 minutes with increasing salivary radioactivity over time.

## Abstract

Prostate-specific membrane antigen (PSMA) is present in high amounts in salivary glands, but it is unclear whether labeled binders of PSMA are excreted in the saliva.

Ten patients with prostate cancer underwent whole-body [18F]DCFPyL PET/CT (NCT03181867), and saliva samples were collected between 0-120 minutes post-injection. [18F]DCFPyL salivary excretion was measured over 120 minutes and expressed as %ID/g. Protein-associated binding was estimated by the percentage of [18F]DCFPyL versus parent radiotracer.

All PET scans of 10 patients (69 ± 8 years) with histologically confirmed prostate cancer (PSA= 2.4 ± 2.4, and Gleason Grade = 6-9) showed high uptake of [18F]-DCFPyL in salivary glands while 8 patients demonstrated high uptake in the saliva at 45 minutes. The intact [18F]-DCFPyL (98%) was also confirmed in the saliva samples at 120 min with increasing salivary radioactivity between 30-120 min.

Systemically injected [18F]DCFPyL shows salivary gland uptake, an increasing amount of which is secreted in saliva over time and is not maximized by 120 minutes post-injection. Although probably insignificant for diagnostic studies, patients undergoing PSMA-targeted therapies should be aware of radioactivity in saliva.